HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home Publications, News & Events

Tuesday22 August 2017

东方网 : 遇见免疫曙光

oriental daily

隨著医疗科技日新月异,自体免疫治疗性疫苗(Human Initiated Therapeutic Vaccine,HITV)的研发,让面对著癌细胞復发或转移的病人,犹如在汪洋中抓到一块浮木,重燃起一线生存的希望。

於2005年研发的自体免疫治疗性疫苗(HITV),为晚期癌症病人带来了希望,尤其是患有弥漫型大B细胞淋巴瘤(Diffuse Large B Cells Lymphoma,DLBCL)却经歷常规治疗失效,正面对癌细胞復发或转移的病人。这类病人也称为復发性或顽固瀰漫性大型B细胞淋巴癌(Relapsed/Refractory Diffuse Large B Cells Lymphoma)病人。

由莲见贤一郎医生(Dr.Kenichiro Hasumi)研发的HITV疗法,主要机制是藉由特製的肿瘤抗原来教导人体免疫细胞辨识癌细胞,並辅以免疫调节剂来强化病人的免疫系统,以抵御顽强的癌细胞,並降低肿瘤復发或转移的发生。

此治疗对已经无法接受常规治疗的重症病人而言,不但能够帮助他们改善疼痛等不適症状,也能提升病人的生活品质,延长生命。

Read more ...

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks